Research and Development Expenses Breakdown: Agios Pharmaceuticals, Inc. vs Evotec SE

Biotech R&D: Agios vs. Evotec's Decade of Innovation

__timestampAgios Pharmaceuticals, Inc.Evotec SE
Wednesday, January 1, 201410037100012404000
Thursday, January 1, 201514182700018343000
Friday, January 1, 201622016300018108000
Sunday, January 1, 201729268100017614000
Monday, January 1, 201834132400035619000
Tuesday, January 1, 201941089400058432000
Wednesday, January 1, 202036747000063945000
Friday, January 1, 202125697300072200000
Saturday, January 1, 202227991000076642000
Sunday, January 1, 202328890300057519000
Monday, January 1, 2024301286000
Loading chart...

Unleashing the power of data

A Decade of Innovation: R&D Spending in Biotech

In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Agios Pharmaceuticals, Inc. and Evotec SE have demonstrated contrasting strategies in their R&D investments.

Agios Pharmaceuticals has consistently outpaced Evotec SE, with its R&D expenses peaking in 2019 at nearly four times that of Evotec. This aggressive investment strategy underscores Agios's dedication to pioneering new therapies. However, post-2019, Agios's R&D spending saw a decline, dropping by approximately 30% by 2023, reflecting a possible shift in strategic focus or resource allocation.

Conversely, Evotec SE has shown a steady increase in R&D spending, with a notable 500% rise from 2014 to 2022. This gradual increase highlights Evotec's commitment to sustainable growth and innovation. As the biotech landscape evolves, these spending patterns offer insights into each company's future trajectory.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025